Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?

Table 2 Clinical studies of second-line monotherapeutic regimens

Ref.	Regimen	Sample size	RR1	PFS/TTP (mo)	Med OS (mo)	1 yr survival
Jacobs et al[16], 2004	Rubitecan	198	11%	1.9	3.5	NR
Burris et al[15], 2005	Rubitecan	58	5.2%	2.0	3.1	9%
Yi et al[78], 2009	Irinotecan	33	9%	2.0	6.6	NR
Takahara et al[79], 2013	Irinotecan	56	3.6%	2.9	5.3	NR
Ko et al[17], 2013	Nanoliposomal irinotecan	40	7.5%	2.4	5.2	25%
Oettle et al[18], 2000	Paclitaxel	18	5.6%	NR	4.1	NR
Maeda et al[19], 2011	Paclitaxel	30	10%	NR	6.7	NR
Cereda et al[20], 2008	Docetaxel	10	0%	1.5	4.0	0%
Hosein et al[22], 2013	Nab-Paclitaxel	19	5%	1.7	7.3	37%
Boeck et al[24], 2007	Capecitabine	39	0%	2.3	7.6	NR
Bodoky et al[59], 2012	Capecitabine	38	7.9%	2.2	5.0	NR
Morizane et al[25], 2009	S-1	40	15%	2.0	4.5	14%
Todaka et al[26], 2010	S-1	52	3.8%	2.1	5.8	12%
Mizuno et al[28], 2013	S-1	67	6%	1.9	5.9	NR
Ioka et al[27], 2013	Best fluoropyrimidine2	40	10%	3.8	7.5	NR
Fukahori et al[80], 2012	Gemcitabine3	27	14%	2.6	8.0	NR
Androulakis et al[81], 2005	Oxaliplatin	18	0%	NR	3.5	NR
Boeck et al[82], 2007	Pemetrexed	52	3.8%	1.6	4.7	NR
Ulrich-Pur et al[48], 2003	Raltitrexed	19	0%	2.5	4.3	0%
Kindler et al[83], 2008	Arsenic trioxide	13	0%	1.6	3.8	0%

¹Intent-to-treat analysis;

²S-1 (67.5%), uracil-tegafur (20%), or 5-fluorouracil (12.5%);

³S-1 refractory disease. Nab-paclitaxel: Albumin-bound nanoparticle paclitaxel; NR: Not reported; PFS: Progression free survival; OS: Overall survival; TTP: Time to progression.